Posted by Michael Wonder on 07 Feb 2022
Everest Medicines announces first drug approval of Trodelvy in Singapore for second-line metastatic triple negative breast cancer
6 February 2022 - Singapore Health Sciences Authority approval marks the first in a series of expected approvals of Trodelvy in Asia.
Everest Medicines announced today that the Health Sciences Authority of Singapore has approved Trodelvy (sacituzumab govitecan) for the treatment of adult patients with unresectable locally advanced or metastatic triple negative breast cancer who have received two or more prior systemic therapies, at least one of them for metastatic disease.
